TY - JOUR
T1 - Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia
AU - Churchman, Michelle L.
AU - Low, Jonathan
AU - Qu, Chunxu
AU - Paietta, Elisabeth M.
AU - Kasper, Lawryn H.
AU - Chang, Yunchao
AU - Payne-Turner, Debbie
AU - Althoff, Mark J.
AU - Song, Guangchun
AU - Chen, Shann Ching
AU - Ma, Jing
AU - Rusch, Michael
AU - McGoldrick, Dan
AU - Edmonson, Michael
AU - Gupta, Pankaj
AU - Wang, Yong Dong
AU - Caufield, William
AU - Freeman, Burgess
AU - Li, Lie
AU - Panetta, John C.
AU - Baker, Sharyn
AU - Yang, Yung Li
AU - Roberts, Kathryn G.
AU - McCastlain, Kelly
AU - Iacobucci, Ilaria
AU - Peters, Jennifer L.
AU - Centonze, Victoria E.
AU - Notta, Faiyaz
AU - Dobson, Stephanie M.
AU - Zandi, Sasan
AU - Dick, John E.
AU - Janke, Laura
AU - Peng, Junmin
AU - Kodali, Kiran
AU - Pagala, Vishwajeeth
AU - Min, Jaeki
AU - Mayasundari, Anand
AU - Williams, Richard T.
AU - Willman, Cheryl L.
AU - Rowe, Jacob
AU - Luger, Selina
AU - Dickins, Ross A.
AU - Guy, R. Kiplin
AU - Chen, Taosheng
AU - Mullighan, Charles G.
N1 - Funding Information:
We thank K. Georgopolous and S. Nutt for providing Ikzf1 +/− mice and the St. Jude Children’s Research Hospital Flow Cytometry and Cell Sorting Shared Resource, Cell Tissue and Imaging Center, and Small Animal Imaging Facility. We thank D. Link for discussions regarding Prrx1-Cre; Ai9 mice. This work was supported by the American Lebanese Syrian Associated Charities of St. Jude Children’s Research hospital, NCI Cancer Center Support Grant P30 CA021765, NCI grant R25 CA23944 (M.J.A.), a Stand Up to Cancer Innovative Research Grant (C.G.M.), the Pew Charitable Trusts (C.G.M.), American Association for Cancer Research/Aflac Career Development Award (C.G.M.), an American Society of Hematology Scholar Award (C.G.M.), and ECOG grants: U10 CA21115 and U24-CA114737. This project has been funded in part with federal funds from the National Cancer Institute, NIH, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views of policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the United States Government.
Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2015/9/14
Y1 - 2015/9/14
N2 - Alterations of IKZF1, encoding the lymphoid transcription factor IKAROS, are a hallmark of high-risk acute lymphoblastic leukemia (ALL), however the role of IKZF1 alterations in ALL pathogenesis is poorly understood. Here, we show that in mouse models of BCR-ABL1 leukemia, Ikzf1 and Arf alterations synergistically promote the development of an aggressive lymphoid leukemia. Ikzf1 alterations result in acquisition of stem cell-like features, including self-renewal and increased bone marrow stromal adhesion. Retinoid receptor agonists reversed this phenotype, partly by inducing expression of IKZF1, resulting in abrogation of adhesion and self-renewal, cell cycle arrest, and attenuation of proliferation without direct cytotoxicity. Retinoids potentiated the activity of dasatinib in mouse and human BCR-ABL1 ALL, providing an additional therapeutic option in IKZF1-mutated ALL.
AB - Alterations of IKZF1, encoding the lymphoid transcription factor IKAROS, are a hallmark of high-risk acute lymphoblastic leukemia (ALL), however the role of IKZF1 alterations in ALL pathogenesis is poorly understood. Here, we show that in mouse models of BCR-ABL1 leukemia, Ikzf1 and Arf alterations synergistically promote the development of an aggressive lymphoid leukemia. Ikzf1 alterations result in acquisition of stem cell-like features, including self-renewal and increased bone marrow stromal adhesion. Retinoid receptor agonists reversed this phenotype, partly by inducing expression of IKZF1, resulting in abrogation of adhesion and self-renewal, cell cycle arrest, and attenuation of proliferation without direct cytotoxicity. Retinoids potentiated the activity of dasatinib in mouse and human BCR-ABL1 ALL, providing an additional therapeutic option in IKZF1-mutated ALL.
UR - http://www.scopus.com/inward/record.url?scp=84942371671&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942371671&partnerID=8YFLogxK
U2 - 10.1016/j.ccell.2015.07.016
DO - 10.1016/j.ccell.2015.07.016
M3 - Article
C2 - 26321221
AN - SCOPUS:84942371671
SN - 1535-6108
VL - 28
SP - 343
EP - 356
JO - Cancer Cell
JF - Cancer Cell
IS - 3
ER -